CC-95251 + cetuximab

**CC-95251 + cetuximab** is an investigational combination therapy consisting of CC-95251, a monoclonal antibody targeting signal regulatory protein alpha (SIRPα), administered with cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody. CC-95251 blocks SIRPα, disrupting the CD47-SIRPα axis—the "don't eat me" signal—enabling macrophage-mediated phagocytosis and immune response against cancer cells. Cetuximab inhibits EGFR signaling, blocking cell proliferation and promoting antibody-dependent cellular cytotoxicity. The combination is being assessed in a phase 1 study for advanced unresectable solid tumors, particularly colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), and other advanced solid cancers. The study is sponsored by Celgene and includes dose escalation and expansion parts to determine safety, tolerability, and recommended phase 2 dosing[1][3][4].